Eisai Co Ltd (ESALY.PK)

ESALY.PK on OTC Markets Group

52.26USD
27 Feb 2015
Change (% chg)

$-0.61 (-1.15%)
Prev Close
$52.87
Open
$52.32
Day's High
$52.32
Day's Low
$52.26
Volume
482
Avg. Vol
11,177
52-wk High
$52.88
52-wk Low
$35.79

ESALY.PK

Chart for ESALY.PK

About

Eisai Co., Ltd. is mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of drugs for pharmaceutical, over-the-counter and diagnostic uses. The Others segment manufactures and... (more)

Overall

Beta: -0.11
Market Cap(Mil.): $15,477.72
Shares Outstanding(Mil.): 296.57
Dividend: 0.60
Yield (%): 2.83

Financials

  ESALY.PK Industry Sector
P/E (TTM): 53.96 38.99 40.21
EPS (TTM): 0.97 -- --
ROI: 4.37 17.01 16.34
ROE: 6.74 17.53 17.27
Search Stocks

FDA approves Eisai's thyroid cancer drug

- The U.S. Food and Drug Administration said it approved Japan's Eisai Co Ltd's drug to treat the most common form of thyroid cancer more than two months ahead of the review date.

13 Feb 2015

REFILE-UPDATE 1-FDA approves Eisai's thyroid cancer drug

Feb 13 - The U.S. Food and Drug Administration said it approved Japan's Eisai Co Ltd's drug to treat the most common form of thyroid cancer more than two months ahead of the review date.

13 Feb 2015

BRIEF-Oncodesign enters into services agreement with Eisai

* Says it has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

17 Dec 2014

BRIEF-Hikma Pharma says in partnership with Eisai for epilepsy treatment drug

* Hikma Enters Partnership With Eisai For Distribution Of First-in-class Epilepsy Treatment Fycompa In Middle East

13 Oct 2014

FDA approves Eisai drug for chemotherapy-associated nausea

- The U.S. Food and Drug Administration said on Friday it has approved Japanese pharmaceutical company Eisai's drug Akynzeo to treat nausea and vomiting in patients undergoing chemotherapy for cancer.

10 Oct 2014

FDA approves Eisai drug for chemotherapy-associated nausea

Oct 10 - The U.S. Food and Drug Administration said on Friday it has approved Japanese pharmaceutical company Eisai's drug Akynzeo to treat nausea and vomiting in patients undergoing chemotherapy for cancer.

10 Oct 2014

Long-awaited diet pill gets U.S. approval

- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

11 Sep 2014

Long-awaited diet pill gets U.S. approval

- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

10 Sep 2014

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $102.51 -0.29
GlaxoSmithKline plc (GSK.L) 1,541.50p -12.50
Novartis AG (NOVN.VX) CHF97.45 -0.70
Merck & Co., Inc. (MRK.N) $58.54 -0.42
AstraZeneca plc (AZN.L) 4,469.50p +4.50
Pfizer Inc. (PFE.N) $34.32 -0.27
Bristol-Myers Squibb Co (BMY.N) $60.92 -0.54
Bristol-Myers Squibb Co (BMYMP.PK) $1,000.00 --
Sanofi SA (SASY.PA) €87.70 +0.16
Roche Holding Ltd. (ROG.VX) CHF258.80 -0.20

Earnings vs. Estimates

Search Stocks